Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin for Cognitive and Olfactory Function in T2DM with MCI
NCT06085703Completed
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of henagliflozin in type 2 diabetes mellitus (T2DM) and Mild Cognitive Impairment (MCI) (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Change of olfactory brain activation by fMRI at 16 weeks. Started Apr 2024; status: completed.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT06085703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06085703.